An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Stomach Neoplasms
Interventions
DRUG

Sunitinib

50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed

Trial Locations (18)

100

Pfizer Investigational Site, Taipei

333

Pfizer Investigational Site, Kwei-Shan

16132

Pfizer Investigational Site, Genova

60020

Pfizer Investigational Site, Ancona

100036

Pfizer Investigational Site, Beijing

210002

Pfizer Investigational Site, Nanjing

510515

Pfizer Investigational Site, Guangzhou

Unknown

Pfizer Investigational Site, Beijing

Pfizer Investigational Site, Hong Kong

Pfizer Investigational Site, Shatin

Pfizer Investigational Site, Kashiwa

Pfizer Investigational Site, Suntougun

Pfizer Investigational Site, Chuo-ku

4200-072

Pfizer Investigational Site, Porto

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

135-710

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY